Michael G Cohen1, Andrew D Althouse2, Robert M Arnold3, Hailey W Bulls3, Douglas White4, Edward Chu5, Margaret Rosenzweig6, Kenneth Smith2, Yael Schenker3. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA. 2. Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 3. Palliative Research Center, Division of General Internal Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh, PA. 4. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 5. Division of Hematology-Oncology, Department of Medicine and Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA. 6. University of Pittsburgh School of Nursing, Pittsburgh, PA.
Abstract
PURPOSE: Providers have cited fear of taking away hope from patients as one of the principal reasons for deferring advance care planning (ACP). However, research is lacking on the relationship between ACP and hope. We sought to investigate the potential association between ACP and hope in advanced cancer. METHODS: This is a cross-sectional analysis of baseline data from a primary palliative care intervention trial. All patients had advanced solid cancers. Three domains of ACP were measured using validated questions to assess discussion with oncologists about end-of-life (EOL) planning, selection of a surrogate decision maker, and completion of an advance directive. Hope was measured using the Hearth Hope Index (HHI). Multivariable regression was performed, adjusting for variables associated with hope or ACP. RESULTS: A total of 672 patients were included in this analysis. The mean age was 69.3 ± 10.2 years; 54% were female, and 94% were White. Twenty percent of patients (132 of 661) reported having a discussion about EOL planning, 51% (342 of 668) reported completing an advance directive, and 85% (565 of 666) had chosen a surrogate. There was no difference in hope between patients who had and had not had an EOL discussion (adjusted mean difference in HHI, 0.55; P = .181 for adjusted regression), chosen a surrogate (adjusted HHI difference, 0.31; P = .512), or completed an advance directive (adjusted HHI difference, 0.11; P = .752). CONCLUSION: In this study, hope was equivalent among patients who had or had not completed 3 important domains of ACP. These findings do not support concerns that ACP is associated with decreased hope for patients with advanced cancer.
PURPOSE: Providers have cited fear of taking away hope from patients as one of the principal reasons for deferring advance care planning (ACP). However, research is lacking on the relationship between ACP and hope. We sought to investigate the potential association between ACP and hope in advanced cancer. METHODS: This is a cross-sectional analysis of baseline data from a primary palliative care intervention trial. All patients had advanced solid cancers. Three domains of ACP were measured using validated questions to assess discussion with oncologists about end-of-life (EOL) planning, selection of a surrogate decision maker, and completion of an advance directive. Hope was measured using the Hearth Hope Index (HHI). Multivariable regression was performed, adjusting for variables associated with hope or ACP. RESULTS: A total of 672 patients were included in this analysis. The mean age was 69.3 ± 10.2 years; 54% were female, and 94% were White. Twenty percent of patients (132 of 661) reported having a discussion about EOL planning, 51% (342 of 668) reported completing an advance directive, and 85% (565 of 666) had chosen a surrogate. There was no difference in hope between patients who had and had not had an EOL discussion (adjusted mean difference in HHI, 0.55; P = .181 for adjusted regression), chosen a surrogate (adjusted HHI difference, 0.31; P = .512), or completed an advance directive (adjusted HHI difference, 0.11; P = .752). CONCLUSION: In this study, hope was equivalent among patients who had or had not completed 3 important domains of ACP. These findings do not support concerns that ACP is associated with decreased hope for patients with advanced cancer.
Authors: Toby C Campbell; Elise C Carey; Vicki A Jackson; Biren Saraiya; Holly B Yang; Anthony L Back; Robert M Arnold Journal: Cancer J Date: 2010 Sep-Oct Impact factor: 3.360
Authors: Sangeeta C Ahluwalia; Fukai L Chuang; Anna Liza M Antonio; Jennifer L Malin; Karl A Lorenz; Anne M Walling Journal: J Oncol Pract Date: 2011-11 Impact factor: 3.840
Authors: Rebecca L Sudore; Hillary D Lum; John J You; Laura C Hanson; Diane E Meier; Steven Z Pantilat; Daniel D Matlock; Judith A C Rietjens; Ida J Korfage; Christine S Ritchie; Jean S Kutner; Joan M Teno; Judy Thomas; Ryan D McMahan; Daren K Heyland Journal: J Pain Symptom Manage Date: 2017-01-03 Impact factor: 3.612
Authors: Claire L Becker; Robert M Arnold; Seo Young Park; Margaret Rosenzweig; Thomas J Smith; Douglas B White; Kenneth J Smith; Yael Schenker Journal: Contemp Clin Trials Date: 2017-01-16 Impact factor: 2.226
Authors: Michael G Cohen; Andrew D Althouse; Robert M Arnold; Hailey W Bulls; Douglas B White; Edward Chu; Margaret Q Rosenzweig; Kenneth J Smith; Yael Schenker Journal: Cancer Date: 2021-11-17 Impact factor: 6.860